The effect of fish oil on restenosis was evaluated in patients undergoing coronary balloon angioplasty. In addition to routine pharmacotherapy, subjects were given 2.8 g of eicosapentanoic acid (EPA) daily. Treatment was started within twenty-four hours after successful percutaneous transluminal coronary angioplasty (PTCA). After six months of therapy, participants were subjected to coronary arteriography, exercise scintigraphy, exercise electrocardiography, or clinical evaluation.
Follow-up evaluation involved 97 coronary lesions in 85 patients. Partial or significant restenosis occurred in 36.5% of patients and 33 % of vessels. The presence of severe stenosis before PTCA, dissection, thrombus, multilesion PTCA, and template bleeding time values were not correlated with restenosis. Dilation of the left anterior descending (LAD) and a residual stenosis≥ 35 % were associated with restenosis.
Approximately 20% of the patients related difficulty in taking the fish oil. Furthermore, these results show no advantage over expected restenosis rates.
Get full access to this article
View all access options for this article.
References
1.
Sacks FM: Current and potential clinical indications of fish oil, 1988 .
2.
Mehta J., Lopez I., Wargovich T.: Eicosapentaenoic acid: Its relevance in atherosclerosis and coronary artery disease. Am J Cardiol59:155-159, 1987.
3.
Herold P., Kinsella J.: Fish oil consumption and decreased risk of cardiovascular disease: a comparison of findings from animal and human feeding trials. Am J Clin Nutr43:566-598,1986.
4.
Zeller F., Spears C.: Fish oil: Effectiveness as a dietary supplement in the prevention of heart disease. Drug Intelligence, Clin Pharm21:584-589, 1987.
5.
Schacky CV: Prophylaxis of atherosclerosis with marine omega-3 fatty acids. Ann Int Med107:890-899, 1987.
6.
Lee T., Hoover R., Williams J., et al: Effect of dietary enrichment with elcosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil functionN Eng J Med312:1217-1224,1985.
7.
Weiner B., Ockene I., Levine P., et al: Inhibition of atherosclerosis by cod-liver oil in a hyperilipidemic swine model. N Eng J Med315:841-845, 1986.
8.
Davis H., Bridenstine R., Vesselinovitch D., et al: Fish oil inhibits development of atherosclerosis in rhesus monkeys . Arterlosierosis7:441-449, 1987.
9.
Dehmer G., Popma J., van den Berg E., et al: Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Eng J Med319:733-40,1988.
10.
Milner M., Gallino R., Leffingwell A., et al: High dose omega-3 fatty acid supplementation reduces clincal restenosis after coronary angioplasty (abstract). Circulation78:(Supple 2):4, abstract No. 2527, 1988.
11.
Slack J., Pinkerton C., VanTassel J., et al: Can oral fish oil supplementation minimize re-stenosis after percutaneous transluminal coronary angioplasty?, Journal American College of Cardiology9:64A, 1987.
12.
Grigg L., Kay T., Manolas E., et al: Does Max-EPA lower the risk of restenosis after PTCA:A prospective randomized trial. Circulation76:(Suppl 4):214, abstract No. 0850, 1987.
13.
Reis G., Sipperly M., Boucher T., et al: Results of a randomized, double-blind placebo-controlled trial of fish oil for prevention of restenosis after PTCA. Abstracts of the 61 st Scientific Sessions II-Circulation (Suppl 2) 78:4 Abstract No. 1159, 291, 1988.
14.
Cunningham D., Kumar B., Siegel B., et al: Aspirin inhibition of platelet deposition at angioplasty sites: Demonstration by platelet scintigraphy . Radiology151: 487-490,1984.
15.
Schwartz L. , Bourassa M., Lesperance J., et al: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Eng J Med318:1714-1719, 1988.
16.
Ellis D., Roubin G., Wilentz J., et al: Results of a randomized trial of heparin and aspirin vs aspirin alone for prevention of acute closure (AC) and restenosis (R) after angioplasty (PTCA). Abstracts of the 60th Scientific Sessions IVCirculation (Suppl IV) 76: 213, abstract No. 0848,213,1987.
17.
Mabin T., Holmes D., Smith H., et al: Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol5:198-202, 1985.
18.
Mata L., Bosch X., David P., et al: Clinical and angiographic assessment 6 months after double vessel percutaneous coronary angioplasty. J Am Coll Cardiol6:1239-1244, 1985 .
19.
Rapold H., David P., Val P., et al: Restenosis and its determinants in first and repeat coronary,angioplastyEur Heart J8-575-586, 1987.
20.
Vandormael M., Deligonul U., Kern M., et al: Restenosis after multilesion percutaneous transluminal coronary angioplasty. Am J Cardiol60:44B-27B, 1987.
21.
Finci L., Meier B., Bruyne B., et al: Angiographic follow-up after multivessel percutaneous transluminal coronary angioplasty. Am J Cardiol60:467-470, 1987.
22.
Rapold J., David P., Val P.: Restenosis and its determinants in first and repeat coronary angioplasty. Eur Heart J8:575-586, 1987.
23.
Roubin G., King S., Douglas J.: Restenosis after percutaneous transluminal coronary angioplasty: The Emory University Hospital experience. Am J Cardiol60:39B-43B, 1987.
24.
Black A., Namay D., Niederman A., et al: Tear or dissection after coronary angioplasty, morphologic correlates of an ischemic complication. Circulation79:1035-1042, 1989.
25.
Wijns W., Serruys, P.Relber J., et al: Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scinigraphy . Am J Cardiol55:357-361, 1985.
26.
Breisblatt W., Wetland F., Spaccavento L.: Stress thallium-201 imaging after coronary angioplasty predicts restenosis and recurrent symptoms . J Am Coll Cardiol12:1199-204,1988.
27.
O'Keefe, J.Lapeyre A., Holmes D., et al: Usefulness of early radionuclide angiography for identifying low-risk patients for late restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol61:51-54, 1988.
28.
Cequier A., Bonan R., Crepeau J., et al: Restenosis and progression of coronary atherosclerosis after coronary angioplasty. J Am Coll Cardiol12:49-55, 1988.
29.
Joelson J., Most A., Williams D.: Angiographic findings when chest pain recurs after successful percutaneous transluminal coronary angioplasty. Am J Cardiol60:792-795,1987.
30.
Holmes D., Vlietstra R., Smith H., et al: Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung and Blood Institute. Am J Cardiol53:77C-81C, 1984.
31.
Clowes A., Karnowsky M.: Suppression by heparin of smooth muscle cell proliferation in injured arteries . Nature265-625-626, 1977.
32.
Pow T., Varricchione T., Jacobs A., et al: Does pretreatment with heparin prevent abrupt closure following PTCA?JACC11:2, abstract No. 238-A, 1988.
33.
Grigg L., Kay T., Manolas E., et al: Does Max-EPA lower the risk of restenosis after PTCA: A prospective randomized trial. Circulation76,I V-214, abstract No. 0850.
34.
White C., Knudson M., Schmidt D., et al: Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: Results from a randomized placebo-controlled multicenter trial. Abstracts of to the 60th Scientific SessionsCirculation, (Suppl IV)78:IV-213, abstract No. 0849,213, 1987.
